Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Background: Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia.
Obesity is an independent risk factor for AF. Anticoagulants have been strongly …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Current literature on the safety and efficacy of direct oral anticoagulants (DOACs) in patients
of extreme weights are limited, however, they are still being prescribed in these populations …

What is known and objective Direct oral anticoagulants (DOACs) are increasingly prescribed
instead of warfarin for chronic anticoagulation for ease of dosing, fewer interactions, and …

The effectiveness and safety of direct oral anticoagulants (DOAC) compared with warfarin
remains uncertain in obese patients. We assessed the comparative effectiveness and safety …

Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …

Currently, direct oral anticoagulants (DOACs) are the first-line anticoagulant strategy in
patients with non-valvular atrial fibrillation (NVAF). They are characterized by a more …

Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …

The use of direct‐acting oral anticoagulants (DOACs) has increased secondary to the
mounting evidence for comparable efficacy and potentially superior safety to vitamin K …